Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Fedratinib
Drug: Rifampin
Drug: Efavirenz

First Posted Date: 2019-06-12

Last Posted Date: 2020-08-21

Lead Sponsor: Celgene

Target Recruit Count: 32

Registration Number: NCT03983239

Locations: 🇺🇸
Covance Clinical Research Unit Inc - Dallas, Dallas, Texas, United States

ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: midazolam
Drug: PF-06651600
Drug: efavirenz

First Posted Date: 2018-12-04

Last Posted Date: 2019-03-26

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT03762928

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults

Phase 4

Terminated

Conditions: HIV-1-infection

Interventions: Drug: B/F/TAF
Drug: Atripla
Drug: B/F/TAF Placebo
Drug: Atripla Placebo

First Posted Date: 2018-05-22

Last Posted Date: 2022-12-14

Lead Sponsor: University of Alberta

Target Recruit Count: 28

Registration Number: NCT03532425

Locations: 🇨🇦
University of Alberta, Edmonton, Alberta, Canada

Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana

Completed

Conditions: Drug Interaction
Contraceptive Usage
HIV Infections

Interventions: Drug: dolutegravir
Device: ENG implant
Drug: Efavirenz

First Posted Date: 2017-11-08

Last Posted Date: 2020-02-05

Lead Sponsor: Columbia University

Target Recruit Count: 148

Registration Number: NCT03336346

Locations: 🇧🇼
Botswana-UPenn Partnership, Gaborone, Botswana

Neuropsychiatric Side Effects of Efavirenz in Children Living With HIV

Completed

Conditions: Efavirenz
Medication Adherence
Child Behavior
Drug-Related Side Effects and Adverse Reactions
Cognitive Symptom

Interventions: Drug: Nevirapine
Drug: Efavirenz
Drug: Lopinavir-Ritonavir Drug Combination

First Posted Date: 2017-07-24

Last Posted Date: 2018-07-10

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 144

Registration Number: NCT03227653

Locations: 🇹🇿
Mawenzi Regional Hospital, Moshi, Kilimanjaro Region, Tanzania
🇹🇿
Kilimanjaro Christian Medical Centre, Moshi, Kilimanjaro Region, Tanzania
🇹🇿
Kiboroloni Dispensary, Moshi, Tanzania

and more 3 locations

ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Dolutegravir
Drug: Atripla
Drug: Truvada
Drug: Tenofovir Alafenamide

First Posted Date: 2017-04-20

Last Posted Date: 2023-02-08

Lead Sponsor: Professor Francois Venter

Target Recruit Count: 1110

Registration Number: NCT03122262

Locations: 🇿🇦
Wits RHI Yeoville Clinic, Johannesburg, Gauteng, South Africa
🇿🇦
Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng, South Africa
🇿🇦
Shandukani Research Centre, Johannesburg, Gauteng, South Africa

and more 1 locations

Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Tenofovir
Drug: Lamivudine
Drug: Efavirenz

First Posted Date: 2016-10-26

Last Posted Date: 2020-02-18

Lead Sponsor: Shanghai Public Health Clinical Center

Target Recruit Count: 184

Registration Number: NCT02945163

Locations: 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
🇨🇳
Yunnan provincial infectious disease hosipital, Kunming, Yunnan, China
🇨🇳
The Second Hospital of Nanjing, Nanjing, Jiangsu, China

Optimization of Antiretroviral Therapy

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Tenofovir disoproxil fumarate
Drug: Lamivudine
Drug: Efavirenz

First Posted Date: 2016-10-17

Last Posted Date: 2020-02-18

Lead Sponsor: Shanghai Public Health Clinical Center

Target Recruit Count: 184

Registration Number: NCT02935075

Locations: 🇨🇳
Yunnan AIDS care center, Kunming, Yunnan, China
🇨🇳
The Second Hospital of Nanjing, Nanjing, Jiangsu, China
🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China

Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid

Phase 1

Conditions: HIV

Interventions: Drug: Efavirenz
Drug: tenofovir /emtricitabine
Drug: tenofovir/lamivudine
Drug: lamivudine/zidovudine
Drug: Rifinah or local generics

First Posted Date: 2016-07-14

Last Posted Date: 2017-06-21

Lead Sponsor: St Stephens Aids Trust

Target Recruit Count: 35

Registration Number: NCT02832778

Locations: 🇺🇬
Infectious Diseases Insitute, Kampala, P.O. Box 22418, Uganda
🇬🇧
Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom

Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women

Phase 2

Completed

Conditions: HIV
Contraception

Interventions: Drug: Levonorgestrel
Drug: Efavirenz

First Posted Date: 2016-03-30

Last Posted Date: 2024-10-03

Lead Sponsor: University of Nebraska

Target Recruit Count: 28

Registration Number: NCT02722421

Locations: 🇺🇬
Infectious Diseases Institute, Kampala, Uganda

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy